Table 1.

Characteristics of Class II–restricted TCR Transgenic Mice

		HNT(15)		D011.10(16)		MBP-1		MBP-2		2B4(33)		5C.C7(31)
Peptide*		HA126-138		OVA323-339		Ac1-11		Ac1-11		cyt. c		cyt. c
										84-103		84-103
Restriction‡		I-Ad		I-Ad		I-Au		I-Au		I-Ek		I-Ek
CD4/Cd8§		3:1		7:1		6–10:1		15–25:1		9–13:1		15–20:1
Thymic
abnormality‖		None		Mild		Moderate		Severe		Severe		Severe
Peripheral
AICD¶		Yes		Yes		Yes		Yes		Yes		Yes
Decline in
No. T cells**		Yes		Yes		No		No		Yes		Yes
Th subset
Low dose††		nd		Th1 and Th 2¶¶, **		Th1		Th1		nd		nd
High dose§§		nd		Th2		Th2		Th2		nd		nd
Background‖   ‖		B10.D2		BALB/c		PL/J		PL/J		B10.BR		B10.A

MBP-1 refers to the Ac1-11–specific TCR transgenic line in which the α and β transgenes are integrated autosomally. MBP-2 refers to the Ac1-11– specific TCR transgenic line in which the α and β transgenes are integrated on the X chromosome.  

^*  The peptide for which the TCR is specific.  

^‡The class II molecule for which the TCR is restricted.  

^§ The ratio of CD4⁺ cell to CD8⁺ cells. Normal ratio is 2:1.  

^‖ The extent of the thymic abnormality observed as determined by hematoxylin and eosin staining.  

^¶ Whether T cells in the periphery undergo AICD after soluble peptide administration.  

^** Whether a decline in the number of CD4⁺ T cells in the periphery occurs after soluble peptide administration.  

^†† Th subset induced in peripheral CD4⁺ T cells after soluble low dose (or low affinity) peptide administration.  

^§§ Th subset induced in peripheral CD4⁺ T cells after soluble high dose (or affinity) peptide administration.  

^∥ 

^∥ Background strain on which experiments were performed.  

^¶¶ Experiments were performed in vitro (38).  

^** At very low doses, Th2 responses were observed (38). nd, not determined.